Estrogen Receptor Antagonist global drug patents, pharmaceutical manufacturers and generics

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Stemline Therap	ORSERDU	elacestrant dihydrochloride	TABLET;ORAL	217639-001	Jan 27, 2023		RX	Yes	No	10,385,008	⤷ Subscribe	Y	Y		⤷ Subscribe
Stemline Therap	ORSERDU	elacestrant dihydrochloride	TABLET;ORAL	217639-002	Jan 27, 2023		RX	Yes	Yes	10,385,008	⤷ Subscribe	Y	Y		⤷ Subscribe
Stemline Therap	ORSERDU	elacestrant dihydrochloride	TABLET;ORAL	217639-001	Jan 27, 2023		RX	Yes	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Stemline Therap	ORSERDU	elacestrant dihydrochloride	TABLET;ORAL	217639-002	Jan 27, 2023		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Stemline Therap	ORSERDU	elacestrant dihydrochloride	TABLET;ORAL	217639-001	Jan 27, 2023		RX	Yes	No	11,819,480	⤷ Subscribe				⤷ Subscribe
Stemline Therap	ORSERDU	elacestrant dihydrochloride	TABLET;ORAL	217639-002	Jan 27, 2023		RX	Yes	Yes	11,819,480	⤷ Subscribe				⤷ Subscribe
Stemline Therap	ORSERDU	elacestrant dihydrochloride	TABLET;ORAL	217639-001	Jan 27, 2023		RX	Yes	No	10,420,734	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Estrogen Receptor Antagonist Drug Class List